Wyeth

Abbott Gmbh & Co Kg

Janssen Sciences Ireland Uc

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Angela Widom

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Michael Roguska

Paul Sakorafas

Nicholas W Warne

Subhashis Banerjee

Thor Las Holtet

Elaine Joy Derbyshire

Daniel Edward Tracey

Sara Carmen

John Gawain Elvin

Michael Paskind

Alexander Robert Duncan

Amy Venturini

Stuart Friedrich

Sarah Leila Du Fou

Stephen Smith

Samuel Goldman

Debra D Donaldson

Davinder Gill

Xiang-Yang Tan

Marion T Kasaian

Angela Myles

John L Knopf

Jose William Saldanha

Kimberly Ann Marquette

James Callaway

Lori J Fitz

Jack Steven Jacobsen

Ivan Lieberburg

Eric Feyfant

Laura Lin

Kevin Delos Parris

Michael Grundman

Angela Kantor

Tania Shane

Bruce Jacobson

Ronald Black

Lars Ekman

Keith M Gregg

Nancy L Wood

Amy Sze Pui Tam

Wagner Marcelo Zago

Macy X Jin

Manuel J Buttini

Gene G Kinney

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

Nucleic acids encoding IL-13 binding agents

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Growing community of inventors

Acton, MA, United States of America

Angela Widom